Related references
Note: Only part of the references are listed.Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant
Jeffrey J. Bednarski et al.
BLOOD (2022)
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
Melissa M. Berrien-Elliott et al.
BLOOD (2022)
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
Mark Gurney et al.
FRONTIERS IN IMMUNOLOGY (2022)
Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
Chantal Reina-Ortiz et al.
CELLS (2022)
New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy
Nathaniel Oberholtzer et al.
CELLS (2022)
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
Mark P. Rubinstein et al.
JOURNAL OF IMMUNOLOGY (2022)
The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
Sana Belkahla et al.
SCIENTIFIC REPORTS (2022)
Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity
Karoliina Tuomela et al.
FRONTIERS IN IMMUNOLOGY (2022)
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
Nerea Allende-Vega et al.
SCIENTIFIC REPORTS (2022)
Generating natural killer cells for adoptive transfer: expanding horizons
Soumyadipta Kundu et al.
CYTOTHERAPY (2021)
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
Chantal Reina-Ortiz et al.
ONCOIMMUNOLOGY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Kevin Conlon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance
Javier Traba et al.
FRONTIERS IN IMMUNOLOGY (2021)
Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells
Alexandros Karampatzakis et al.
FRONTIERS IN IMMUNOLOGY (2021)
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
Takahiro Miyazaki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
Sigrid P. Dubois et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
Hassan Dana et al.
ACTA PHARMACEUTICA SINICA B (2021)
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Sarah B. Reusing et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity
Yue Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
Daniel A. Vallera et al.
CANCERS (2021)
FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma
Austin B. Bigley et al.
BLOOD ADVANCES (2021)
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
Susanne Wingert et al.
MABS (2021)
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Emily J. Pomeroy et al.
MOLECULAR THERAPY (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
Martin Villalba et al.
FRONTIERS IN IMMUNOLOGY (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance
Tania Calvo et al.
SCIENTIFIC REPORTS (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes
Kashyap R. Patel et al.
GLYCOBIOLOGY (2020)
Frequency analysis of the g.7081T>G/A and g.10872T>G polymorphisms in the FCGR3A gene (CD16A) using nested PCR and their functional specific effects
Camilo Andres Perez-Romero et al.
GENES AND IMMUNITY (2019)
Recognition of Human IgG1 by Fcγ Receptors: Structural Insights from Hydrogen-Deuterium Exchange and Fast Photochemical Oxidation of Proteins Coupled with Mass Spectrometry
Liuqing Shi et al.
BIOCHEMISTRY (2019)
A Phase I/II Trial of Cetuximabin Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Elizabeth L. McMichael et al.
CLINICAL CANCER RESEARCH (2019)
The Evolutionary Arms Race between Virus and NK Cells: Diversity Enables Population-Level Virus Control
Sarah K. A. Savoy et al.
VIRUSES-BASEL (2019)
The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III
Rina Yogo et al.
SCIENTIFIC REPORTS (2019)
Altered cancer metabolism in mechanisms of immunotherapy resistance
Rishab Ramapriyan et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25
Megan C. Duggan et al.
ONCOIMMUNOLOGY (2018)
Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells
Hemant K. Mishra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Restricted processing of CD16a/Fc γ receptor IIIa N-glycans from primary human NK cells impacts structure and function
Kashyap R. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
Katja Srpan et al.
JOURNAL OF CELL BIOLOGY (2018)
Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice
Roisin M. Loftus et al.
NATURE COMMUNICATIONS (2018)
Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
Diego Sanchez-Martinez et al.
THERANOSTICS (2018)
CD16a with oligomannose-type N-glycans is the only low-affinity Fc gamma receptor that binds the IgG crystallizable fragment with high affinity in vitro
Ganesh P. Subedi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
Mira Tout et al.
CLINICAL PHARMACOKINETICS (2017)
Not Just an Adhesion Molecule: LFA-1 Contact Tunes the T Lymphocyte Program
Navin Kumar Verma et al.
JOURNAL OF IMMUNOLOGY (2017)
Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile
Christine W. Bruggeman et al.
JOURNAL OF IMMUNOLOGY (2017)
Transmembrane features governing Fc receptor CD16A assembly with CD16A signaling adaptor molecules
Alfonso Blazquez-Moreno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
Gillian Dekkers et al.
FRONTIERS IN IMMUNOLOGY (2017)
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Frank Cichocki et al.
CANCER RESEARCH (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy
Ganesh P. Subedi et al.
BIOCHEMISTRY (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
Alysia A. Ahmed et al.
JOURNAL OF STRUCTURAL BIOLOGY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Reshmi Parameswaran et al.
NATURE COMMUNICATIONS (2016)
Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12
Amanda R. Campbell et al.
BMC MEDICAL GENOMICS (2015)
Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals
Jaewon Lee et al.
IMMUNITY (2015)
Cytokine secretion and NK cell activity in human ADAM17 deficiency
Pinchas Tsukerman et al.
ONCOTARGET (2015)
Super-resolution Imaging of the Natural Killer Cell Immunological Synapse on a Glass-supported Planar Lipid Bilayer
Peilin Zheng et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
Molecular mechanisms of natural killer cell activation in response to cellular stress
C. J. Chan et al.
CELL DEATH AND DIFFERENTIATION (2014)
ADAM17-Mediated Shedding of FcγRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation
Laurie Lajoie et al.
JOURNAL OF IMMUNOLOGY (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin
Shivani Srivastava et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency
Tianxiang Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions
Ilwoong Hwang et al.
INTERNATIONAL IMMUNOLOGY (2012)
The Unique Cytoplasmic Domain of Human FcγRIIIA Regulates Receptor-Mediated Function
Xiaoli Li et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Patrick Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells
Emily M. Mace et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
Janelle A. Olson et al.
BLOOD (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation
Mami Shibata-Koyama et al.
GLYCOBIOLOGY (2009)
Novel Human Interleukin-15 Agonists
Xiaoyun Zhu et al.
JOURNAL OF IMMUNOLOGY (2009)
Cytokine-induced memory-like natural killer cells
Megan A. Cooper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function
Charles-Antoine Dutertre et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Formation and function of the lytic NK-cell immunological synapse
Jordan S. Orange
NATURE REVIEWS IMMUNOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells
Serena Cecchetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Self-tolerance of natural killer cells
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human antibody - Fc receptor interactions illuminated by crystal structures
JM Woof et al.
NATURE REVIEWS IMMUNOLOGY (2004)
LFA-1 contributes an early signal for NK cell cytotoxicity
DF Barber et al.
JOURNAL OF IMMUNOLOGY (2004)
Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship
S Dall'Ozzo et al.
CANCER RESEARCH (2004)
SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells
R Galandrini et al.
BLOOD (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement
R Paolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The structure of a human type III Fcγ receptor in complex with Fc
S Radaev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex
P Sondermann et al.
NATURE (2000)
In vivo natural killer cell activities revealed by natural killer cell-deficient mice
S Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
MK Kennedy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
